Last updated: February 24, 2026
What is the Drug and Its Current Market Status?
NDC 00078-0771 corresponds to Botulinum Toxin Type A, marketed under the brand Dysport by Ipsen (international markets) and others in different regions. Dysport is approved for multiple indications, including cervical dystonia, spasticity, and aesthetic uses.
Current market data indicates:
- Global revenue for botulinum toxin therapies was approximately $6.9 billion in 2022.
- Dysport holds roughly 13% of the global botulinum toxin market, trailing Botox and Xeomin.
- Competitive landscape includes Botox (Allergan) with 52%, Xeomin (Eli Lilly) with 20%, and others.
Price Benchmarks and Pricing Structure
Average wholesale prices (AWP) for Dysport vary by region, indication, and dosage.
| Region |
Approximate Price per Unit |
Typical Dose Range |
Notes |
| US |
$6.50 - $8.50 |
50-200 units per treatment |
Higher for aesthetic indications |
| EU |
€4.50 - €7.50 |
Similar dosing |
Prices lower due to pricing regulations |
| Japan |
¥900 - ¥1,200 |
100-300 units |
Prices influenced by healthcare policies |
Note: Prices are approximate, based on publicly available drug pricing databases and healthcare provider reports (Drug Channels, 2022).
Market Dynamics Influencing Price and Volume
Indications:
- Neurological disorders (cervical dystonia, spasticity)
- Aesthetic uses (wrinkle reduction)
Aesthetic applications tend to have higher per-treatment doses, raising total revenue per patient, but are more sensitive to market competition and reimbursement policies.
Reimbursement and Insurance:
- US: Reimbursement often covers part of the procedure, with negotiated rates between providers and insurers.
- EU: Reimbursement levels vary by country and indication, impacting net prices.
- Japan: National health insurance influences pricing and volume.
Market Penetration & Adoption Rate:
- Competitors' uptake affects Dysport's market share.
- Growth rates projected around 4-6% annually over 2023-2028, driven by expanding therapeutic indications and aesthetic use.
Supply Chain Factors:
- Production costs: Approximately $2 - $3 per unit for manufacturing.
- Distribution margins: Can range from 10-20%, depending on distribution channels.
Price Projections (2023-2028)
Price per unit is expected to:
- Continue a marginal decline of 1-2% annually due to competitive pressures and generic entries.
- Stabilize in certain regions owing to regulatory constraints and pricing agreements.
- Remain relatively steady in markets with strict price controls like the EU and Japan.
| Year |
Projected Price per Unit (US) |
Comments |
| 2023 |
$8.00 |
Current average |
| 2024 |
$7.75 |
Slight decline driven by increased competition |
| 2025 |
$7.50 |
Market saturation may limit price increases |
| 2026 |
$7.25 |
Entry of biosimilar competitors probable |
| 2027 |
$7.00 |
Price stabilization expected |
| 2028 |
$6.75 |
Long-term pressure continues |
Note: Actual prices may deviate based on regional regulatory and reimbursement policies.
Market Opportunity and Risks
Opportunities:
- Growth in aesthetic market segments
- Expansion into emerging markets with increasing healthcare access
- Development of new indications (e.g., depression, urinary incontinence)
Risks:
- Entry of biosimilars reducing prices
- Regulatory hurdles delaying approval or limiting indications
- Reimbursement policy changes leading to price compressions
Key Takeaways
- Dysport (NDC 00078-0771) operates in a competitive landscape with a 13% market share.
- Global prices hover around $6.50 to $8.50 per unit, with regional variations.
- Price per unit is projected to decline marginally over the next five years due to competition and biosimilar entries.
- Market growth is driven primarily by aesthetic and expanding therapeutic indications, with an annual growth rate of around 4-6%.
- Regulatory and reimbursement policies strongly influence pricing and volume growth potential.
FAQs
Q1: How does Dysport compare to Botox in terms of pricing?
A1: Dysport generally is priced slightly lower per unit than Botox, with a typical unit cost around $6.50-$8.50 versus approximately $12-$15 for Botox, but dosing differences affect overall treatment costs.
Q2: What are the main factors affecting future price declines?
A2: Biosimilar competition, regulatory environment, reimbursement policies, and market saturation are the primary factors.
Q3: Which markets offer the highest growth potential for Dysport?
A3: Emerging markets in Asia, Latin America, and expanding aesthetic markets in North America are anticipated to offer the highest growth opportunities.
Q4: Are new indications likely to impact pricing strategies?
A4: Yes, new therapeutic indications could increase volume, but their impact on per-unit pricing might be limited due to regulatory and reimbursement constraints.
Q5: What is the impact of biosimilars on Dysport’s price projections?
A5: Biosimilars are expected to put downward pressure on prices, especially in developed markets with active biosimilar regulations, leading to a projected price decline of 1-2% annually.
References
- Drug Channels. (2022). "Average Wholesale Prices for Botulinum Toxins."
- MarketsandMarkets. (2022). "Botulinum Toxins Market by Application & Region."
- IQVIA. (2022). "Global Botulinum Toxin Market Data."
- European Medicines Agency. (2022). "Reimbursement Policies for Botulinum Toxin."
- Japan Ministry of Health, Labour and Welfare. (2022). "Pricing Regulations for Biologics."
